ADAM17 and cancer: In a meta-analysis of the expression of ADAM10 and ADAM17 in GC, their increased expression was associated with T3-4 cancer more than T1-2 cancer (OR = 0.29, 95% CI = 0.21–0.40, p < 0.0001), N-positive cancer more than N-negative cancer (OR = 4.36, 95% CI = 2.25–8.45, p < 0.0001), cancer with distant metastasis more than cancer without metastasis (OR = 0.09, 95% CI = 0.02–0.37, p = 0.0008) [179].